ERBB2 and breast carcinoma: In the GSE173839 dataset of HER2-negative stage II/III breast cancer patients on the durvalumab with olaparib and paclitaxel arm, it seemed that higher CCC score was correlated with pCR (p< 0.01, Figure 10A).